Despite this, there are few real-world data evaluating DAA therapy within prison settings. In the era of direct acting antiviral (DAA) therapy which is highly efficacious, time-efficient and safe, modelling studies have identified the benefit of increasing HCV treatment uptake amongst PWIDs to reduce community prevalence via treatment-as-prevention. This is a result of financial, logistical and prisoner barriers to HCV care within correctional facilities. However, very few prisoners are treated for HCV while incarcerated. Due to the close relationship between injecting drug use, incarceration and chronic HCV, the prevalence of HCV is up to 40 times greater within correctional facilities compared with the community. Targeted treatment of people who inject drugs (PWID) is important for achieving the WHO goals of eliminating viral hepatitis, which will have a significant impact on reducing HCC rates. The global prevalence of HCV is approximately 1.0%, and in developed countries, injecting drug use continues to be the primary risk factor in incident cases. Hepatitis C virus (HCV) remains a major public health threat worldwide, responsible for 500,000 deaths annually hepatocellular carcinoma (HCC) remains one of the major causes of HCV-related mortality.
0 kommentar(er)
